Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06586255 · ClinicalTrials.gov registry record · Phase 1
Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer
A Phase 1 study of Bladder Cancer and Urothelial Carcinoma Bladder, sponsored by Abramson Cancer Center at Penn Medicine.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT06586255 is a Phase 1 study of Bladder Cancer and Urothelial Carcinoma Bladder that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 10 participants, below the 12,754-participant average among 175 other Bladder Cancer trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06586255, a Phase 1 study of Bladder Cancer and Urothelial Carcinoma Bladder, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this Phase I study is to establish the safety of adjuvant concurrent immunotherapy and radiation therapy for urothelial bladder cancer.
Conditions Studied
Interventions
- RADIATION Concurrent Immunotherapy and Radiation Therapy
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-04-29 |
| Est. Completion | 2027-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06586255
The ClinicalTrials.gov registry entry for NCT06586255 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,754-participant average among 175 other Bladder Cancer trials with a reported enrollment target (100% lower). The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Bladder Cancer appearing as the primary indexed condition, and to 1 intervention - of which Concurrent Immunotherapy and Radiation Therapy is the first listed.
NCT06586255 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06586255 about?
NCT06586255 is a clinical study titled "Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer". The primary objective of this Phase I study is to establish the safety of adjuvant concurrent immunotherapy and radiation therapy for urothelial bladder cancer.
What is the current status of trial NCT06586255?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2025-04-29. Estimated completion is 2027-04.
What conditions does trial NCT06586255 study?
This clinical trial studies the following conditions: Bladder Cancer, Urothelial Carcinoma Bladder.
What interventions are being tested in trial NCT06586255?
The interventions under investigation include: Concurrent Immunotherapy and Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT06586255?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06586255 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Sacituzumab Govitecan Plus EV in Metastatic UC
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.